Fate Therapeutics (NASDAQ: FATE) is developing clinical-stage cellular immunotherapies for cancer and immune disorders, with an opportunity in 2017 to broadly establish the leading NK (natural killer) cell clinical franchise. The Company’s programs include:

• A first-in-class adaptive memory NK cell product candidate (FATE-NK100) designed to enhance direct tumor cell killing, resist immune checkpoints and promote endogenous T-cell anti-tumor response.
  • Investigational New Drug (IND) cleared by FDA for initiation of clinical investigation in acute myelogenous leukemia (AML)
• A next-generation mobilized peripheral blood graft (ProTmune) for the prevention of graft-versus-host disease (GvHD) in patients with hematologic malignancies undergoing transplant
  • Phase 1/2 PROTECT study ongoing
  • ProTmune granted FDA Fast Track and Orphan Drug designations
• A human induced pluripotent stem cell (iPSC) platform that enables the generation of master cell lines to renewably create off-the-shelf engineered NK- and T-cell cancer immunotherapies
  • Collaborations with University of Minnesota and Memorial Sloan Kettering for product candidate development

The Company raised $57 million in Nov 2016 from a leading investor syndicate including Redmile Group LLC, BVF Partners L.P., EcoR1 Capital LLC, and Franklin Advisers, Inc., and had approximately $100 million in cash following the financing.  Institutional ownership exceeds 70%.

Bio-Path Holdings (NASDAQ: BPTH) is a clinical stage biotechnology company developing therapeutics for the treatment of cancer and systemic diseases. Bio-Path's RNAi technology for drug development, DNAbilize™, uses a novel liposomal antisense DNA platform that allows for systemic delivery of nucleic acids without toxicity. Using DNAbilize™ clinicians can inhibit the production of proteins involved in cancer and block pathways involved in disease progression.  
 

COMPANY HIGHLIGHTS

• Proprietary antisense and liposome delivery technology breakthrough for DNA drugs, potentially solving the challenges of delivering these molecules directly to target cells without side effects
• Original technology licensed from The MD Anderson Cancer Center. Company maintains strong relationship with the Cancer Center
• Strong IP position with composition of matter and method patents for antisense targets and manufacturing
• Lead product candidate, prexigebersen (Liposomal Grb2) formerly BP1001, in the clinic for blood cancers and in development for solid tumors. Second product candidate, BP1002 (Liposomal Bcl2) is IND-ready
• Promising clinical data for BP1001 shows that the drug has been well tolerated with possible anti-leukemic effects, including patients stabilizing for extended treatment

Learn More